In conclusion, although the pathogenic role of EECs in initiating enteric α‐synuclein pathology and the pathophysiological role of altered GLP‐1 responses in PD remain controversial, the dysfunction of the enteroendocrine system, possibly via alterations of the gut microbiome, represents an interesting therapeutic target in PD. This evidence concerns the gene GLP1R and Parkinson disease.